First National Bank Sioux Falls Invests $330,000 in Thermo Fisher Scientific Inc. $TMO

Key Points

• First National Bank Sioux Falls has invested approximately $330,000 in shares of Thermo Fisher Scientific Inc., purchasing 813 shares during the second quarter.
• Insider trading reports indicate that CAO Joseph R. Holmes and CEO Marc N. Casper have both sold shares recently, decreasing their ownership by 14.24% and 0.35% respectively.
• Brokerages have recently issued mixed ratings on Thermo Fisher Scientific, with HSBC downgrading it to "hold", while UBS and Scotiabank have raised their price targets, indicating a broad interest in the stock's performance.

First National Bank Sioux Falls purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 813 shares of the medical research company's stock, valued at approximately $330,000.

Other institutional investors have also modified their holdings of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $25,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the period. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific in the first quarter valued at approximately $30,000. Finally, Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last three months. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMO. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. UBS Group lifted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $479.48 on Friday. The company has a market cap of $181.06 billion, a P/E ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The business's 50-day simple moving average is $466.86 and its 200 day simple moving average is $451.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% on a year-over-year basis. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.